TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nanobiotix ( (NBTX) ) has shared an announcement.
On November 11, 2025, Nanobiotix announced its participation in the Jefferies London Healthcare Conference, scheduled for November 17, 2025. The company’s CEO, Laurent Levy, and CFO, Bart van Rhijn, will engage in a fireside chat at the event, which will be webcast live. This participation underscores Nanobiotix’s commitment to engaging with the investor community and highlights its strategic positioning in the biotechnology industry.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases. Founded in 2003 and headquartered in Paris, France, the company is listed on Euronext Paris and the Nasdaq Global Select Market. Nanobiotix owns over 25 patent families related to nanotechnology platforms with applications in oncology, bioavailability and biodistribution, and central nervous system disorders.
Average Trading Volume: 90,301
Technical Sentiment Signal: Buy
Current Market Cap: $1.07B
See more insights into NBTX stock on TipRanks’ Stock Analysis page.